Table of Contents
Executive Summary — 5
Table: Switzerland Pharmaceuticals
And Healthcare Industry SWOT — 6
Switzerland Economic
SWOT — 7
Switzerland Political
SWOT — 7
Pharmaceutical Business Environment
Ratings — 8
Table: Western Europe Pharmaceutical Business
Environment Rankings — 8
Limits Of Potential
Returns — 9
Risks To Realisation Of
Returns — 9
Switzerland – Market
Summary — 11
Regulatory Regime — 12
Recent Regulatory Developments — 13
Recent
Approvals — 13
Intellectual Property
Regime — 14
Pricing Regime — 15
Recent
Pricing System Developments — 16
Reimbursement
Regime — 18
Industry Developments — 20
Epidemiology — 20
Health
Insurance — 21
Healthcare Sector
Financing — 22
Pharmaceutical
Sector — 23
Pharmaceutical Wholesale and Retail
Sector — 23
Company Developments — 25
Research And Development Sector — 29
Biotechnology
Sector — 32
Industry Forecast
Scenario — 34
Overall Market
Forecast — 34
Table: Switzerland – Pharmaceutical
Expenditure Indicators, 2004-2013 — 35
Key Growth Factors
– Industry — 36
Table: Switzerland – Health
Expenditure Indicators, 2004-2013 — 37
Key Growth Factors
– Macroeconomic — 38
Table: Switzerland -
Macroeconomic Forecasts, 2008-2012 — 39
Prescription
Market Forecasts — 41
Table: Switzerland –
Prescription Market Indicators, 2004-2013 (CHFmn unless otherwise
stated) — 42
OTC Market Forecast — 43
Table: Switzerland – OTC Market Indicators, 2004-2013 (CHFmn unless
otherwise stated) — 44
Patented Market
Forecasts — 45
Table: Switzerland – Patented
Pharmaceutical Market Indicators, 2004-2013 (CHFmn unless otherwise
stated) — 45
Generics Market
Forecasts — 46
Table: Switzerland – Generics Market
Indicators, 2004-2013 (CHFmn unless otherwise stated) — 47
Export/Import Forecasts — 48
Table: Switzerland –
Pharmaceuticals Export And Import Indicators (US$mn),
2004-2013 — 49
Other Healthcare
Forecasts — 50
Other Healthcare
Forecasts — 50
Table: Switzerland – Other Healthcare
Indicators, 2004-2013 — 50
Medical
Devices — 51
Table: Switzerland Medical Device Market
Indicators, 2006-2012 (US$bn unless otherwise stated) — 52
Key Risks to BMI’s Forecast Scenario — 53
Competitive Landscape — 54
Company
Monitor — 55
Leading Multinational
Manufacturers — 55
GlaxoSmithKline
(GSK) — 55
Pfizer — 57
Sanofi-Aventis — 58
Merck & Co — 59
Indigenous Manufacturers — 60
Novartis — 60
Roche — 64
Merck-Serono — 67
Country Snapshot: Switzerland
Demographic Data — 69
Section 1:
Population — 69
Table: Demographic Indicators,
2005-2030 — 69
Table: Rural/Urban Breakdown,
2005-2030 — 70
Section 2: Education And
Healthcare — 70
Table: Education,
2002-2005 — 70
Table: Vital Statistics,
2005-2030 — 70
Section 3: Labour Market And Spending
Power — 71
Table: Employment Indicators,
2001-2006 — 71
Table: Consumer Expenditure, 2000-2012
(US$) — 71
Table: Average Annual Wages,
2000-2012 — 72
BMI Forecast
Modelling — 73
How We Generate Our Pharmaceutical Industry
Forecasts — 73
Pharmaceutical Business Environment Ratings
Methodology — 74
Ratings Overview — 74
Table: Pharmaceutical Business Environment Indicators — 75
Weighting — 76
Table: Weighting Of
Components — 76
Sources — 76
| 
View Cart
